Background/aim: Lung cancer, a predominant contributor to cancer mortality, is characterized by diverse etiological factors, including tobacco smoking and genetic susceptibilities. Despite advancements, particularly in nonsmall-cell lung cancer (NSCLC), therapeutic options for lung squamous cell carcinoma (LUSC) are limited. Transposable elements (TEs) and their regulatory proteins, such as tigger transposable element derived (TIGD) family proteins, have been implicated in cancer development. TIGD1, upregulated in various cancers, including LUSC, lacks a defined function. The aim of our study was to elucidate the biological functions, associated pathways, and interacting proteins of TIGD1.
Materials And Methods: The GSE229260 microarray dataset was investigated using the GEO2R tool to identify the differentially expressed genes (DEGs) in TIGD1 silenced in A549 lung cancer cells in contrast to controls. Enrichment analyses and protein-protein interaction (PPI) network construction were performed to uncover key pathways using KEGG and STRING analyses. Hub genes were determined through the intersection of DEGs with lung cancer-related genes via Cytoscape software and the cytoHubba plug-in, and their functions were analyzed. Immune and stromal scores of hub genes were also evaluated using the ESTIMATE algorithm.
Results: Analyzing microarray data from TIGD1-silenced A549 NSCLC cells, a total of 13 upregulated DEGs and 1 downregulated DEGs were identified. The TIGD1-associated DEGs revealed significant involvement in crucial molecular pathways, including the PI3K/AKT, FOXO, and p53 signaling pathways. The hub genes AKT1, BRAF, SRC, GAPDH, CCND1, CDKN2A, CTNNB1, KRAS, MYC, and TP53 emerged as central regulators of cell proliferation, apoptosis, and protein metabolism. The hub genes exhibited negative correlations with immune and stromal components in the tumor microenvironment, suggesting their potential as biomarkers for lung cancer therapy.
Conclusion: This study elucidates the potential functions of TIGD1 in lung cancer and identifies promising biomarker candidates associated with TIGD1 gene expression, presenting potential therapeutic targets for lung cancer therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673667 | PMC |
| http://dx.doi.org/10.55730/1300-0144.5920 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proteomic analysis reveals anticancer mechanisms of Bhallataka taila in inhibiting lung cancer progression and metastasis.
Mol Omics
January 2025
Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore 575018, India.
Lung cancer remains the leading cause of cancer-related deaths worldwide due to its poor prognosis. Despite significant advancements in the understanding of cancer development, improvements in diagnostic methods, and multimodal therapeutic regimens, the prognosis of lung cancer has still not improved. Therefore, it is reasonable to look for newer and alternative medicines for treatment.
View Article and Find Full Text PDFIntroduction: Lung cancer ranks among the foremost causes of mortality associated with cancer. Ensartinib is a highly effective oral anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive lung adenocarcinoma. This report presents a case of acute renal failure attributed to the administration of ensartinib.
View Article and Find Full Text PDFPrognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study.
World J Orthop
December 2024
Department of Orthopaedic Surgery, The University of Tokyo, Bunkyo-ku 113-8655, Tokyo, Japan.
Background: Accurate data on the prognosis of bone metastases are necessary for appropriate treatment. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of gene mutation-negative non-small cell lung cancer (GMN-NSCLC).
Aim: To investigate the prognostic factors in patients with bone metastases from GMN-NSCLC following ICI use.
Targeting ion channels: innovative approaches to combat cancer drug resistance.
Theranostics
January 2025
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Ion channels, as functional molecules that regulate the flow of ions across cell membranes, have emerged as a promising target in cancer therapy due to their pivotal roles in cell proliferation, metastasis, apoptosis, drug resistance, and so on. Recently, increasing evidence suggests that dysregulation of ion channels is a common characteristic of cancer cells, contributing to their survival and the resistance to conventional therapies. For example, the aberrant expression of sodium (Na) and potassium ion (K) channels is significantly correlated with the sensitivity of chemotherapy drugs.
View Article and Find Full Text PDFAnti-PD1 therapies induce an early expansion of Ki67CD8 T cells in metastatic non-oncogene addicted NSCLC patients.
Front Immunol
January 2025
Laboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. These therapies induced early modifications of the immune response impacting the clinical outcome. Identifying early changes in the immune system was critical to directing the therapeutic choice and improving the clinical outcome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!